Welcome to our dedicated page for Enlivex Ltd. SEC filings (Ticker: ENLV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Enlivex Ltd.’s SEC filings document its status as an Israeli foreign private issuer with ordinary shares listed under ENLV, its clinical-stage Allocetra™ program, and its prediction markets treasury strategy centered on the RAIN token and Rain protocol.
Recent Form 6-K reports furnish current disclosures on regulatory clearances for Allocetra™ in age-related knee osteoarthritis, annual financial results, tokenized representations of the company’s ordinary shares, Rain protocol ecosystem updates, senior secured convertible debt, and the completed corporate name change from Enlivex Therapeutics Ltd. to Enlivex Ltd. The filings also reference registration statements and governance records tied to shareholder approvals and capital structure.
Enlivex Therapeutics Ltd. filed a Form 6-K noting it will host a webinar on August 18, 2025, at 8:00 Eastern Time. During the event, the company plans to present and discuss 3‑month topline results from the Phase IIa stage of its Phase I/IIa ENX-CL-05-001 clinical trial. This double-blind, randomized, placebo-controlled, multi-center study is evaluating its Allocetra™ therapy in patients with moderate-to-severe knee osteoarthritis. The related press release, dated August 14, 2025, is furnished as Exhibit 99.1.